Sheffield Medical Technology Inc., of New York, andHemagen Diagnostics Inc., of Waltham, Mass., arecollaborating to develop an ELISA assay that assessesHIV progression. The target of the antibody-based assayis the non-mutating cellular protein, beta-2-microglobulin, on the surface of replicated HIV.
Abbott Laboratories, of Abbott Park, Ill., was granted aworldwide license to Copiague, N.Y.-based AmericanBiogenetic Sciences Inc.'s Thrombus Precursor Proteinimmunoassay, a blood test to detect cardiovasculardisorders. Abbott also got a one-year option to acquire anon-exclusive license to San Diego-based NovaDxInternational Inc.'s technologies for detecting multipleforms of arthritis.
Sonus Pharmaceuticals, of Bothell, Wash., started PhaseIII studies of EchoGen Emulsion, an ultrasound contrastagent for use in echocardiography.
Jay LawrenceDirector of Computing Phone: 410 563-5383Community of Science Fax: 410 563-5389http://cos.gdb.org
(c) 1997 American Health Consultants. All rights reserved.